Textul licitației

ele caracteristici ale procedurii: The contracting authority shall, on behalf of the four regional health authorities in Norway enter into framework agreements for active substances connected to HAE disease. See Annex 3 Requirement Specifications and The Competition Provisions for detailed information. The active ingredient Icatibant (B06AC02) under the framework agreement 2499a has been extended to 31.01.2026. Icatibant will therefore not be a part of 2599a, but will be included in the next HAE procurement.2.1.1. ScopNatura contractului: BunuriClasificarea principală (cpv): 33600000 Produse farmaceutice2.1.2. Locul de executareȚara: NorvegiaOriunde în țara respectivă2.1.3. ValoareValoarea estimată fără TVA: 375 000 000,00 NOK2.1.4. Informații generaleTemei juridic: Directiva 2014/24/UEAnskaffelsesforskriften - 2.1.6. Motive de excludereSituații similare, în temeiul legislației naționale, cum ar fi falimentul: Is the supplier in a situation where he has been forced debt arrangement? Specify why, under the mentioned circumstances, one is able to carry out the contract, considering the current national p